Articles

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Hematology and Oncology, Department of Medicine, University Hospital Tübingen, Germany
National and Kapodistrian University of Athens, Greece
Hematology, University Hospital Hôtel-Dieu, Nantes, France
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Vancouver General Hospital, BC, Canada
Department of Hematology, University Hospitals Leuven, Belgium
Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France
Universitäts Klinikum Heidelberg, Germany
Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France
Institut Catala d’Oncologia, Hospital Germans Trias I Pujol, Barcelona, Spain
Hospital Universitario La Princesa, Madrid, Spain
Princess Margaret Hospital, Toronto, ON, Canada
Bologna University School of Medicine, Institute of Hematology and Medical Oncology, Bologna, Italy
Hôpital Saint-Antoine, Paris, France
GUZ Moscow City Clinical Hospital S. P. Botkin, Moscow, Russia
Hospital Universitario 12 de Octubre, Madrid, Spain
Hematology and Oncology, Würzburg University Medical Center, Würzburg, Germany
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Clínica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain
Vol. 101 No. 7 (2016): July, 2016 https://doi.org/10.3324/haematol.2015.137083